NIH Study Keeps Synairgen’s Dream Of An Inhaled COVID-19 Therapy Alive
Two Readouts Expected In 2022
SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.
![NIH](https://insights.citeline.com/resizer/v2/27ORX7FBOJPMDH7VB2NI7SIO7M.jpg?smart=true&auth=ae784a63727eccfb8f60c6f86e3c20079e179d859b92b02a566cd4738c935e57&width=700&height=394)
SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.